Tag:
ecallantide
Latest Headlines
Latest Headlines
Red flag forces Cubist to halt Phase II enrollment
Cubist Pharmaceuticals slammed the brakes on enrollment for two mid-stage studies of ecallantide after the safety monitoring board noted a higher death rate among patients taking a high dose of the
FDA staffers question Dyax studies
Staffers at the FDA have raised questions regarding Dyax's ecallantide, an experimental drug intended to treat hereditary angioedema. In a review, the agency workers said that Dyax's studies did not
